What if your respiratory patients could achieve symptom control faster?

Fewer treatments, improved outcomes13,14



Aerogen delivers a higher percentage of emitted dose reaching the lower airway of the lungs improving patient outcomes†‡ 2-5,10-16

Vibrating mesh produces consistent particle size of <5μm, allowing 85% of patients to achieve symptom control faster using lessmedication7,14


Aerogen is not a technique dependent device making it easy to use with mild to severe respiratory patients across all respiratory modalities supporting continuity of care17 

Contact us

34%
Drug Deposition 
via Aerogen Ultra2

  1. Aerogen Solo Instruction Manual
  2. Galindo-Filho VC, Ramos ME, Rattes CS, et al. Respir Care. 2015;60(9):1238-1246.
  3. Galindo-Filho VC, Alcoforado L, Rattes C, et al. Respir Med. 2019;153:60-67.
  4. AlQuaimi MM, Fink JB, Ari A. J Respir Dis Lung Dis. 2017;2:1018.
  5. American Association for Respiratory Care SARS CoV-2 Guidance Document. https://www.aarc.org/wp-content/
    6. uploads/2020/03/guidance-document-SARS-COVID19.pdf (accessed 11 Nov 2022). 
  6. Fink JB, Ehrmann S, Li J, et al. J Aerosol Med Pulm Drug Deliv. 2020;33(6):300-304.
  7. Cinesi Gómez C, Peñuelas Rodríguez Ó, Luján Torné M, et al. Med Intensiva (Engl Ed). 2020;44(7):429-438.
  8. Respiratory care committee of Chinese Thoracic Society. Zhonghua Jie He He Hu Xi Za Zhi. 2020;17(0):E020.
  9. Kumar S, Mehta S, Sarangdhar N, et al. Expert Rev Respir Med. 2021;15(4):519-535.
  10. Swarnakar R, Gupta NM, Halder I, et al. Lung India. 2021;38(Supplement):S86-S91.
  11. Aerogen Data on File.

GL-3461-1-EN